Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › United Therapeutics › CEO reported a gift or transfer of 2,060 UTHR shares Insider trades
Why it stands out Gift or transfer — classified separately from trades.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date May 26, 2026
Reporting period Not applicable
Filed with the SEC May 27, 2026 CEO Indirect holding Gift / transfer
Context Classification gift transfer
Code G — gift, bequest or transfer
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
0001106578-26-000061
Filed / recorded May 27, 2026, 12:44 AM UTC
Added to OQRO Oct 6, 2026, 9:34 PM UTC
Data quality Verified: identifiers matched exactly
Issuer UNITED THERAPEUTICS Corp
Reporting person Martine A Rothblatt
Relationship Director, Officer
Officer title Chairperson & CEO
Table Non-derivative (Table I)
Transaction date May 26, 2026
Acquired / disposed Disposed (D)
Ownership form Indirect — By Trust
Footnotes from the filing Bona fide gift of shares Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Mar 25, 2026 Insider · 1 person Insiders: 11 sales (~$5.2M) Mar 26, 2026 Insider · 3 people Insiders: 22 sales (~$11.5M) Mar 27, 2026 Insider · 1 person Insiders: 5 sales (~$2.7M) Mar 30, 2026 Insider · 3 people Insiders: 42 sales (~$12.3M) May 6, 2026 Company filing · Form 8-K · Results Reported its results What came next Jun 26, 2026 Company filing · Form 8-K · Executive change, Shareholder vote Changed a top executive or board member, and held a shareholder vote “As described in Item 5.07 below, on June 26, 2026, at the 2026 Annual Meeting of Shareholders of United Therapeutics Corporation (the Company ), the Company’s shareholders approved the United Therapeutics Corporation 2026 Stock Incentive Plan (the 2026 Plan ).” Jul 22, 2026 Company filing · Form 8-K · Executive change, Reg FD Changed a top executive or board member, and shared information with investors “On July 22, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board.” Aug 5, 2026